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1. Introduction 
Oral lesions are very common in individuals with HIV (human immunodeficiency virus) 
infection and AIDS (acquired immune deficiency syndrome). They are reported to occur in 
50% of people infected with HIV and in about 80% of  people diagnosed  with AIDS 
(Palmer, et al., 1996).  Introduction of HAART (highly active anti-retroviral therapy)  in 1996 
has reduced the mortality and morbidity in people affected with HIV and AIDS as well as 
improved their quality of life. It has also resulted in a decrease, to a certain extent, in the 
incidence and prevalence of oral lesions.  
Since HIV infection was first diagnosed in 1981, a variety of oral lesions has been associated 
with infected individuals, and they can be good indicators of the disease in otherwise 
healthy people. Oral lesions can also help determine the progression of the disease. In 
developed countries, CD4 lymphocyte counts and HIV viral load are the two main 
laboratory markers that are used to determine disease progression. However, in certain 
developing countries, people do not always have access to these tests, and severity of the 
oral lesions can serve as good indicators of disease progression.  
Table 1 highlights the importance of diagnosing and treating oral lesions in individuals with 
HIV (Coogan, et al., 2005) 
 
1. Can help diagnose the presence of HIV infection in otherwise healthy individuals 
2. Develop early in an infection 
3. Help determine the progression of HIV infection to AIDS 
4. Entry and end-points in vaccine trials 
5. Used in staging and classification of HIV diseases as determinants of opportunistic 
infection and anti-HIV therapy 
Table 1. Importance of oral manifestations of HIV disease 
1.1 Classification of oral lesions associated with HIV 
The EC-Clearinghouse on oral problems related to HIV infection and WHO Collaborating 
Centre on Oral manifestations of the immunodeficiency virus proposed the classification of 
oral manifestations of HIV infection in September of 1992 based on their strength of 
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association with the presence of HIV infection: ("Classification and Diagnostic Criteria for 
Oral Lesions in HIV Infection. EC-Clearinghouse on Oral Problems Related to HIV Infection 
and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus," 
1993). More recently in 2002,  an international workshop was convened to discuss the 
classification of oral lesions associated with HIV/AIDS almost 2 decades after the virus was 
first identified (Patton, et al., 2002) and it was agreed that the original EC-Clearinghouse 
classification could still be used in current times.  Table 2 summarizes the classification of 
oral lesions associated with HIV.  
 
Group 1: Lesions strongly 
associated with HIV 
infection 
Group 2: Lesions less 
commonly associated with 
HIV infection 
Group 3: Lesions seen in 
HIV infection 
Candidiasis  
Hairy leukoplakia  
Kaposi’s sarcoma 
Non-Hodgkin’s lymphoma 
Periodontal disease (linear 
gingival erythema, 
necrotizing ulcerative 
gingivitis, necrotizing 
ulcerative periodontitis) 
Bacterial infections: 
Mycobacterium avium-
intracellularae 
Mycobacterium tuberculosis 
Melanogic 
hyperpigmentation 
Necrotizing (ulcerative) 
stomatitis 
Salivary gland disease 
Dry mouth due to 
decreased salivary flow 
Unilateral/bilateral 
swelling of salivary glands 
Thrombocytopenia purpura 
Non-specific ulcerations 
Viral infections: 
Herpes simplex virus 
Human papillomavirus  
Condyloma acuminatum 
Focal epithelial hyperplasia 
Verruca vulgaris 
Varicella-zoster virus 
Bacterial infections: 
Actinomyces israelii 
Escherichia coli 
Klebsiella pneumonia 
Cat-scratch disease 
Drug  reactions (ulcerative, 
erythema multiforme, 
lichenoid, toxic 
epidermolysis) 
Epitheliod (bacillary) 
angiomatosis 
Fungal infection other than 
candidiasis 
Cryptococcus neoformans 
Geotrichum candidum 
Histoplasma capsulatum 
Mucoraceae (mucomycosis 
zygomycosis) 
Aspergilus flavus 
Neurological disturbances: 
Facial palsy 
Trigeminal neuralgia 
Table 2. Classification of oral lesions associated with HIV 
In this chapter, we will discuss only those lesions that are commonly seen in persons 
infected with HIV.  
2. Candidiasis 
2.1 Background 
Candidiasis is a common opportunistic infection caused by an overgrowth of the Candida 
microorganisms already present in the oral cavity.  Incidence of oral candidiasis has been 
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high in developing countries (Tukutuku, et al., 1990). Since the discovery of HIV in 1981, 
candidiasis has been shown to be associated with HIV-infected individuals (Gottlieb, et al., 
1981). Previous reports show that oral candidiasis occurs in 54-93% of individuals with 
AIDS (Schmidt-Westhausen, et al., 1991). In recent reports, due to the introduction of anti-
retroviral therapy only 20% of individuals infected with HIV showed oral candidiasis 
(Davies, et al., 2006).  
2.2 Pathogenesis 
Oral candidiasis is primarily caused by a dimorphic ubiquitous Candida albicans. The cell 
wall of Candida is primarily made up of three polysaccharides, mannan, glucan and chitin. 
Candida attaches to oral tissues and dentures with the help of adhesins such as Als1p, Als5p, 
Int1p and Hwp1p (Chaffin, et al., 1998, Hostetter, 1994). These glycoproteins bind to the 
extracellular matrix of mammalian cells such as fibrinogen, laminin and collagen (Chaffin, et 
al., 1998). Candidal adhesion to endothelial surfaces is achieved by the cell surface 
polysaccharide mannan, which binds to complement receptor 3 (CR3), an integrin found on 
human cells (Calderone and Braun, 1991). There is increased association of integrin analogs 
(iC3B and CR3d receptor) and fibronectin receptor with most of the virulent forms of 
Candida (Ollert, et al., 1990). Thus, CR3-like proteins promote adherence of Candida albicans 
to host cells.  
2.3 Clinical features 
There are three clinical forms of candidiasis: pseudo-membranous (thrush), 
erythematous (atrophic) and perioral angular chelitis. Proliferation of pseudo-
membranous fungi forms a gray-white structure composed of inflammatory substrate 
and matted organisms resting on an erythematous base. These lesions are most 
commonly evident on the tongue, buccal mucosa, hard and soft palate and pharyngeal 
tissues. The erythematous form  shows mucosal hyperemia and inflammation with a 
reddened erythematous patches (Calderone and Fonzi, 2001). The mucous membrane 
appears dry, red and glazed.  Affected individuals show burning sensitivity and pain 
sensation of dry mouth, odynophagia, dysgeusia and smell of yeast infection. Angular 
chelitis shows commissural involvement as erythematous/hyperkeratotic with fissuring 
and sensitivity. Individuals receiving HAART show low occurrence of these clinical 
features. Before the emergence of HAART, the incidence of oral candidiasis was 
relatively high in persons with AIDS.  
2.4 Treatment 
An early study for treatment of Candida infections was carried out by Williams in 1977, where 
nystatin was compared to no treatment in 56 patients (Williams, et al., 1977). Since then 
ketoconazole, fluconazole, clotrimazole, itraconazole, neomycin sulphate, colistin, trimethoprin 
and sulphamethoxazole have been tried in combination and at different concentrations for 
treatment of oral candidiasis (Hann, et al., 1982, Owens, et al., 1984, Palmblad, et al., 1992, 
Philpott-Howard, et al., 1993, Rozenberg-Arska, et al., 1991, Vogler, et al., 1987). Most recently 
ketoconazole and clotrimazole were found most effective in treatment of oral candidiasis 
(Worthington, et al., 2002). Initial local treatments are first line of therapy (Bensadoun, et al., 
2008). Mucosal contact for 2 minutes is recommended either by rinsing, gargling or swallowing. 
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Systemic treatments are considered in high-risk patients only when local therapy fails (Charlier, 
et al., 2006). When topical and systemic therapy fails, intravenously administered amphotericin 
B and echinocandins are considered in high-risk patients. Intermittent use of antifungal agents 
has been advocated to prevent development of resistant fungal infections (Samaranayake, et al., 
2002). Recently, gel formulation of fluconazole has proven to be a better alternative treatment 
form than tablet formulation (Nairy, et al.).  
 
 
Fig. 1. Cell wall of Candida albicans 
 
 
Fig. 2. Hypertrophic Candidiasis 
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Fig. 3. Pseudo-membranous Candidiasis 
 
 
Fig. 4. Atrophic/Erythematous Candidiasis 
www.intechopen.com
  
Global View of HIV Infection 
 
84
 
Fig. 5. Angular Chelitis 
3. Hairy leukoplakia 
3.1 Background 
OHL (Oral hairy leukoplakia) is caused by Epstein-Barr virus and was first described in 
1984. 50% of individuals with HIV present with this condition and it is a very good indicator 
of immunosuppression. The lesion usually presents itself when the CD4 cell counts fall 
below 0.3*109/L (Bravo, et al., 2006). According to the CDC (Centers for Disease Control and 
Prevention), this condition has a clear prognostic value in predicting the future 
development of AIDS ("1993 Revised Classification System for HIV Infection and Expanded 
Surveillance Case Definition for AIDS among Adolescents and Adults," 1992). 
3.2 Pathogenesis 
The pathogenesis of OHL is due to the replication of Epstein-Barr virus and increased 
virulence in conjunction with a decrease in local and systemic host immunity.  
3.3 Clinical features 
OHL present themselves as white, corrugated lesions on the lateral surface of the tongue 
and are not painful. There has been a decrease in the incidence of OHL due to the potent 
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anti-retroviral drugs. However, if OHL is seen in an HIV-infected person, it may indicate 
failure of current therapy. Differential diagnosis of this condition includes oral candidiasis, 
lichen planus, other forms of leukoplakia, HPV (human papilloma virus) associated 
intraepithelial neoplasia, and oral squamous cell carcinoma. 
 
 
Fig. 6. Oral Hairy Leukoplakia 
3.4 Treatment 
OHL is a relatively benign condition with low morbidity and does not require any specific 
treatment. Most of the time, these lesions resolve spontaneously. However, several 
treatment options are available for those who feel uncomfortable or have cosmetic concerns 
due to the lesion. Since the lesion is caused by multiplication of the Epstein-Barr virus 
topical and systemic anti-viral agents work effectively in resolving the lesion. High doses of 
Acyclovir (800 mg 5 times a day) (Resnick, et al., 1988), Valacyclovir (1000 mg 3 times a day), 
and Famciclovir (500 mg 3 times a day) have all been shown to  resolve  the lesions in 1-2 
weeks (Schofer, et al., 1987). However, once the effect of the anti-viral agent wears off, the 
lesions can recur several weeks later.  
Topical application of Podophyllin resin in 25% solution has  produced resolution of the 
lesion in 1-2 weeks (Gowdey, et al., 1995). Topical therapy with retinoic acid has also 
been shown to cause resolve the lesions due to inhibition of Epstein-Barr virus 
replication. Ablative and cryotherapy have also had success in treatment of the lesions. 
Although the above treatment options are effective in resolving the lesion, OHL can 
recur several weeks after treatment since none of these agents eliminate the latent state 
of infection.  
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4. Kaposi’s sarcoma 
4.1 Background 
KS (Kaposi’s sarcoma) is an angioproliferative tumor described by the Hungarian 
pathologist Moritz Kaposi in 1872. It is caused by  KSHV (Kaposi’s sarcoma-associated 
herpes virus) or Ǆ2-herpes virus. KSHV belongs to the genus Rhadinovirus and has a DNA 
sequence similar to other rhadinoviruses (Albrecht, et al., 1992). With the introduction of 
HAART in 1996, the incidence of AIDS-related cancers such as KS and NHL (non -
Hodgkin’s lymphoma) has decreased (Shiels, et al., 2008). During the 1980s and early 1990s, 
US population rates of KS increased 30 fold (Eltom, et al., 2002). There were no KS cases 
during 1975-1979, before the advent of AIDS. In an HIV cancer match study, 81% of KS cases 
matched to HIV registries during 1980-2007 (Shiels, et al., 2011). AIDS occurred in a higher 
proportion of patients with Kaposi’s sarcoma in age groups of 0-29 and 30-59 years (Shiels, 
et al., 2011). 
4.2 Pathogenesis 
KS lesions show varying cell diversity. Lesions are flat, comprising of inflammatory cells (T, 
B cells and monocytes). Neovascularization develops prior to development of these lesions 
and contain spindle-shaped cells. This dermal stage progresses to the plaque stage, in which 
the lesions are more indurated, edematous, and red or violet in color.  The lesion eventually 
reaches the nodular stage and is characterized by visible masses with dominant spindle cells 
and inflammatory cells. These spindle cells express lymphatic-specific markers (e.g., 
Podoplanin and lymphatic vessel hyaluronan receptor LYVE-1) as well as participate in the 
signaling process during lymphangiogenesis (Skobe, et al., 1999, Weninger, et al., 1999).  
4.3 Clinical features 
There are four types of KS: classic type, endemic African KS, KS in organ transplant 
recipients, and HIV-infection/AIDS associated KS (Trattner, et al., 1993). KS is the most 
common neoplasm (20-50%) found in HIV-infected individuals (mostly homosexual and 
bisexual men) (Scully, et al., 1991).Oral lesions are evident in 40% of KS (Greenspan and 
Greenspan, 1990).Red or purplish macules, papules or nodules appear most frequently on 
the hard palate (Greenspan and Greenspan, 1990). Unless infected or ulcerated, these lesions 
do not blanch on pressure (Greenspan and Greenspan, 1990). Laryngeal involvement is also 
evident in individuals with KS (Pantanowitz and Dezube, 2006). Primary symptoms are 
hoarseness, throat discomfort, urge to cough, aphonia, dysphagia, stridor, and complete 
airway obstruction. 
4.4 Treatment 
The extent and bulk of the disease determines the therapeutic alternative that needs to be 
considered. Individuals with fewer than five cutaneous lesions are kept on watch until 
rapid proliferation, widespread dissemination or KS-related symptoms become more 
apparent. Treatment with HAART or other anti-retroviral therapies are beneficial and 
have shown histologic regression of existing lesions (Eng and Cockerell, 2004). HAART 
therapy causes inhibition of HIV replication, diminishes the HIV-1 transactivating protein 
Tat, ameliorates the immune response against KSHV, and shows direct anti-angiogenic 
activity (Cattelan, et al., 1999, Pati, et al., 2002, Sgadari, et al., 2002).  Radiotherapy is 
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indicated for lesions on the face, hands and upper extremities, obstructive 
lymphadenopathy, periorbital edema, lesions on soles of the feet, anorectal or genital 
lesions, oral lesions and ulcerating cutaneous lesions. Radiotherapy shows merits in 
symptomatic disease where systemic treatment is not necessary and expensive 
chemotherapy can be avoided (Swift, 1996). If an active opportunistic infection is 
observed, chemotherapeutic agents should be considered. Systemic chemotherapeutic 
treatment is indicated in extensive KS of oral cavity, widespread skin involvement, pedal 
or scrotal edema, symptomatic visceral involvement and flare induced by immune 
reconstitution inflammatory syndrome (Osoba, et al., 2001). Individuals may suffer from 
neutropenia and thrombocytopenia and hence controlled therapy should be the choice of 
treatment. Only nodular and symptomatic lesions of oropharynx should be treated with 
radiation. Recombinant and non-recombinant alpha interferons can be used for treatment 
of epidemic KS (De Wit, et al., 1988).  
 
 
Fig. 7. Kaposi’s Sarcoma 
5. Human Papilloma Virus (HPV) infections 
5.1 Background 
HPV is the leading cause of orpharyngeal carcinomas (D'Souza, et al., Rosenquist, 2005). 
HPV16 is a common cause for the majority of oropharyngeal carcinomas (Kreimer, et al., 
2005) . HPV-positive individuals are most frequently Caucasian and belong to high 
socioeconomic status (Gillison, et al., 2008).  HIV-infected individuals have two to four-fold 
increase in risk for developing HPV-related oral cancers (Gilbert, et al.). HPV has also been 
considered as one of the etiologic factors for OHL (oral hairy leukoplakia) (Fejerskov, et al., 
1977), as shown by identification of HPV antigens and HPV DNA (Loning, et al., 1985). 
HPV-induced OL shows prevalence ranged from 17% to 68.6% (Shroyer, et al., 1993, 
Sugiyama, et al., 2003). 
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5.2 Pathogenesis 
HPV is mainly infectious through expression of oncogenes such as E6/E7 (Al-Bakkal, et al., 
1999),  which cause phosphorylation of CHK2, leading to caspase activation (Al-Bakkal, et 
al., 1999, Moody and Laimins, 2009, Tominaga, et al., 1999). The intrinsic apoptotic pathway 
of caspase activation plays an important role in HPV replication (Moody, et al., 2007). HPV 
proteins flourish and regulate amplification primarily by caspase activation, leading to 
immortalization of the suprabasal layer of epithelium, specifically the keratinocytes (Sakai, 
et al., 1996). 
5.3 Clinical features 
HPV induced oral and pharyngeal cancers are most evident in younger females (<40 years). 
OSCC (oral squamous cell carcinoma) normally occur on the buccal mucosa (2-10%), lip (4-
40%), alveolar ridge (2-18%) retromolar trigonous (2-6%), hard palate (3-6%), floor of mouth 
(25%), ventral two third of tongue (50%), alveolar ridge (2-18%), floor of mouth (25%) and 
oropharynx (25%). Squamous cell carcinoma of the oropharynx most commonly originates 
in the tonsils and tongue base (the two most common sites), pharyngeal walls, and soft 
palate. 
 
 
 
 
 
Fig. 8. Human Papilloma Virus Lesions 
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5.4 Treatment 
Treatment of HPV infection can be achieved either by use of targeted therapy against the 
virus or immune-stimulating therapy. Most dysplastic tissue can be treated by ablative and 
excisional therapy. Use of radiochemotherapy in the form of radiation ± cisplatin or 
cetuximal has shown beneficial results in treatment of oropharyngeal carcinoma. The overall 
survival rate was 60 % in HPV-positive individuals and 73 % in HPV-negative individuals 
(Lill, et al.). 
6. Periodontal lesions associated with HIV 
6.1 Linear Gingival Erythema (LGE) 
6.1.1 Background 
This lesion is also known as ‘red-band gingivitis’ or ‘HIV-associated gingivitis’. LGE is 
commonly seen in immune-compromised individuals and is considered to be a potential 
precursor for necrotizing ulcerative gingivitis (NUG)/ necrotizing ulcerative periodontitis 
(NUP). According to the recent classification of periodontal diseases (Armitage, 1999), LGE 
is classified under ‘Gingival diseases of fungal origin.’ 
6.1.2 Pathogenesis 
There is an increased number of bacteria and Candida species in the gingival sulcus 
associated with LGE. The bacteria seen include those commonly observed in periodontal 
disease such as Bacteriodes gingivalis, Bacteriodes intermedius, Actinomyces viscosus, 
Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans.  
6.1.3 Clinical features 
The lesions present themselves as 2-3 mm wide red band around the marginal gingival of 
the teeth. These lesions are not typically painful, but bleed readily.  
6.1.4 Treatmen 
Typically, no treatment is needed for this condition.  Although LGE is listed under ‘Lesions 
of fungal origin’, it is not typically treated with anti-fungal medications. Mechanical 
removal of plaque and calculus helps reduce inflammation and excessive bleeding. 
Chlorhexidine gluconate (0.12%) mouth rinses can be used twice daily. If the lesion persists, 
systemic antibiotics (metronidazole) may be prescribed to reduce the bacterial load.  
6.2 Necrotizing Ulcerative Gingivitis and Periodontitis (NUG and NUP) 
6.2.1 Background 
NUG is a painful condition of the gingiva characterized by ulcerations, bleeding, and foul 
breath. It is also called Vincent’s infection, Vincent’s angina, or trench mouth. When the 
infection spreads to the alveolar bone, it is called NUP.  Prevalence of NUP in HIV-infected 
individuals has been reported by various researchers. Its prevalence with HIV was reported 
in 1994 as 6% (Glick, et al., 1994). Over a period of a decade, the incidence of HIV in NUP 
patients increased to 69.6% (Shangase, et al., 2004). Recent reports suggest 43% of patients 
with NUP were HIV-seropositive (Phiri, et al.). Studies have shown that HIV-infected 
individuals with NUP are 20.8% more likely to have a CD4+ count lower than 200 (Glick, et 
al., 1994). 
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Fig. 9. Linear Gingival Erythema 
6.2.2 Pathogenesis 
NUP is commonly a progression of NUG  that demonstrates bone loss and clinical 
attachment levels (MacCarthy and Claffey, 1991). Both are primarily caused by bacterial 
infection with microflora consisting of Treponema and Selenomonas species, Prevotella 
intermedia, Fusobacterium nucleatum and Porphyromonas gingivalis (Falkler, et al., 1987, 
Loesche, et al., 1982). Malnutrition, smoking, stress, trauma and preexisting gingivitis are 
other etiologic factors (Peruzzo, et al., 2007, Taiwo, 1993). Most persons with NUG have 
alterations in the immune system making them more prone to microbial infections (Cogen, 
et al., 1983). This immunosuppression is also evident in infection by HIV (Goedert, et al., 
1984). Treponema denticola (T. denticola) is the principal oral helical-shaped anaerobic 
spirochete that plays an essential role in immunosuppression. The disease process is 
mediated through adherence to mucosal surfaces, specific cleavage of cell surface receptors, 
inhibition of host defense mechanisms, penetration in epithelial cells, and induction of 
gingival inflammation and bone resorption. Proteases such as chymotrypsin, phospholipase 
C, oligopeptidase and cystalysin play an important role in pathogenicity (Chi, et al., 2003, 
Ellen and Galimanas, 2005, Fenno and McBride, 1998) and is induced by a range of pro-
inflammatory cytokines such as IL-1ǂ, IL-1ǃ, tumor necrosis factor-ǂ, IL-6 and IL-8 
(Gemmell and Seymour, 1998, Nixon, et al., 2000). These cytokines affect connective tissue 
destruction and alveolar bone desorption (Gemmell and Seymour, 1998). Phosphorylation of 
intracellular receptors such as Fos-c, MKK1, MAP kinase and nuclear factor κB molecules by 
T. denticola affect these changes (Tanabe, et al., 2008).  
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6.2.3 Clinical features 
The clinical characteristics of NUG includes ulcerated and necrotic papillary and marginal 
gingival covered by a yellowish-white or grayish slough or “pseudomembrane”, blunting 
and cratering of papillae, spontaneous bleeding or bleeding on probing, pain and fetid 
breath (Barnes, et al., 1973, Falkler, et al., 1987, Horning and Cohen, 1995).  It may be 
accompanied by fever, lymphadenopathy, and malaise. Progression of gingivitis to NUP is 
commonly associated with clinical attachment loss and alveolar bone destruction.  
 
 
Fig. 10. Necrotizing Ulcerative Periodontitis 
6.2.4 Treatment 
The first treatment for NUG was devised by Dr. S. Schluger in 1949 (Schluger, 
1949).Bacterial pathogens were controlled or  eliminated by mechanical debridement or use 
of antibiotics in earlier days (Johnson and Engel, 1986). Aureomycin and penicillin were the 
first antibiotics considered for treatment of NUG in 1950 (Goldman and Bloom, 1950, 
Montis, 1950). Mechanical treatment consists of scaling and root planing. In addition to 
mechanical debridement, antibiotic and antimicrobial therapies are essential for 
management of NUP. Oxidizing mouthwash such as 3% hydrogen peroxide has also shown 
to have beneficial effects in management of NUG and NUP. 
7. Non-Hodgkin lymphoma 
7.1 Background 
There are three subtypes of on-Hodgkin’s lymphoma (NHL): diffuse large B cell lymphoma 
(DLBCL), Burkitt’s lymphoma (BL) and central nervous system lymphoma (CNSL)(Engels, 
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et al., 2006).  An increase in occurrence of DLBCL (10.2%), BL (27.8%) and CNSL (48.3%) was 
seen in individuals with AIDS during 1990-1995 (Shiels, et al., 2011). The 5-year survival rate 
improved from 1960 to the mid 1970s, but not much after that in the USA (Shiels, et al., 
2011). NHL relates to congenital and acquired immunodeficiency diseases (Filipovich, et al., 
1992). The relative risk of NHL in individuals with AIDS is about 150-250 in Western 
countries and over 1000 in children (Goedert, 2000).  
7.2 Pathogenesis 
The head and neck regions are the most common sites for NHL, showing in 30-40% of cases 
(Economopoulos, et al., 1996). The neoplastic cells express CD20, CD79, BCL-2 and BCL-6, 
most of which are B-cell antigens (Hoefnagel, et al., 2003). The hallmark of B-cell 
malignancies is chromosomal translocation involving the immunoglobulin heavy chain 
(IGH) gene at band 14q32.33 with specific oncogene loci, referred to as the 14q32 
translocation. Among these specific 14q32 translocations, de novo acute leukemia/lymphoma 
with c-MYC and/or BCL6 abnormalities in addition to t(14;18) was characterized by an 
extremely aggressive clinical course with nodal and/or extranodal involvement, and 
massive bone marrow infiltration(Kramer, et al., 1991). Incidence of IGH translocation on B-
cell NHL  has been reported in previous studies (Kramer, et al., 1998). Thus multiple 
involvement of the IGH gene in chromosomal rearrangements is associated with the 
pathogenesis and the progression of NHL.  
 
 
 
 
Fig. 11. Histology of NUP lesion- Infiltration of Spirochetes into the Connective Tissue 
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Stage I 
Involvement of a single lymph node region (I) or a single 
extralymphatic organ or site (IE) 
Stage II 
Involvement of two or more lymph node regions on the same side 
of the diaphragm (II) alone or with localized involvement of an 
extralymphatic organ or site (IIE) 
Stage III 
Involvement of lymph node regions on both sides of the 
diaphragm (III) alone or with localized involvement of an 
extralymphatic organ or site (IIIE) or spleen (IIIS) or both (IIISE) 
Stage IV 
Diffuse or disseminated involvement of one or more 
extralymphatic organs with or without associated lymph node 
involvement 
Table 3. Ann Arbor Classification of Non-Hodgkin’s Lymphomas (Rupniewska, 1979) 
7.3 Clinical features 
Oral NHL lesions are often in disseminated disease states. The most common oral sites of 
involvement are the palate, tonsil, buccal mucosa, floor of the mouth, and the retromolar 
region. These lesions are non-tender, diffuse swellings usually involving the gingiva, buccal 
vestibule and posterior hard palate. Gnathic lesions arise from soft tissue invading the bony 
skeleton. One third of patients show fever, weight loss, adenopathy, night sweats, or 
hepatosplenomegaly. Oral lesions are fluctuant swellings showing ulceration, pain, tooth 
mobility and paresthesia when peripheral nerves are involved (Vega, et al., 2005). Salivary 
gland lymphomas account for approximately 3% of all salivary gland tumors (Barnes, et al., 
1998). About 80% of the cases are reported in parotid gland, 16% in submandibular, 2% in 
sublingual and 2% in minor salivary glands. Affected bony areas show a “punched out” 
pattern that is due to multiple areas of destruction with ill defined radiolucent lesion. 
Involvement of the maxillary sinus will cause opacification with eroded cortical walls and 
associated sinus mass (Fukuda, et al., 1987). The Ann Arbor staging system, originally 
designed for Hodgkin’s disease, is used for NHL as evident above. 
7.4 Treatment 
A prognostic index has been developed by the International NHL prognostic factors project 
based on data from 2,031 patients with aggressive lymphomas treated with regimens 
containing doxorubicin ("A Predictive Model for Aggressive Non-Hodgkin's Lymphoma," 
1993). Analysis of 1274 patients younger than 60 years showed three clinical features 
independently associated with survival: serum LDL (lactate dehydrogenase) levels, tumor 
stage, and their performance status ("A Predictive Model for Aggressive Non-Hodgkin's 
Lymphoma," 1993). Past studies showed the importance of gallium-67 uptake in lymphomas 
as a useful prognostic indicator (Janicek, et al., 1997). The importance of prognostic index is 
that good-risk patients can be identified for standard therapy and poor-risk patients can be 
identified for new research protocols to improve the rate of therapy. With conventional 
therapy only 25% of patients who were gallium-positive midway through therapy  had 
durable responses , while 70% of those who were gallium-negative remained free of disease 
(Janicek, et al., 1997). In patients with stage I or II disease, regional therapy leads to long-
term control, with relapse rate of 44%-47% at 10 years and survival rates of 75% for patients 
younger than 60 years (Vaughan Hudson, et al., 1994). Stage III and IV patients can be 
treated by alkylating agents, combination chemotherapy regimens with 2-4 drugs, and high 
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dose therapy with bone marrow transplant reinfusion(Freedman, et al., 1996, Govindan, et 
al., 2009). 
8. Conclusions 
Thorough examination of the oral cavity should be part of the physical examination for 
everybody, but especially in HIV-positive individuals and those who are at a high risk for 
acquiring HIV infection. Oral lesions can not only compromise the quality of life and 
increase morbidity in patients with HIV/AIDS, but can also serve as indicators for the 
presence of the disease and disease progression. It is also very important for health care 
providers and medical practitioners from different specialties to collaborate in providing the 
overall care for these immune-compromised patients.  
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